EQRx

EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

Retrieved on: 
Monday, November 22, 2021

Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

Key Points: 
  • Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
  • Its our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.
  • Aumolertinib is a novel, irreversible EGFR-TKI that selectively inhibits both EGFR sensitizing and resistance mutations with high selectivity over wild-type EGFR.
  • EQRx and Remaking Medicine are trademarks of EQRx, Inc.
    1World Health Organization, International Agency for Research on Cancer.

EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

Retrieved on: 
Thursday, November 18, 2021

Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development.

Key Points: 
  • Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development.
  • Evotec will lead drug discovery and pre-clinical development efforts, and EQRx will be responsible for clinical development, regulatory and commercialization efforts.
  • In addition to jointly funded research and development activities, Evotec will benefit from the potential commercial success of the assets developed within the partnership through a variable profit share mechanism.
  • We continue to rapidly expand our early-stage development pipeline through access to innovative, next-generation drug discovery and engineering technologies, said Carlos Garcia-Echeverria, Ph.D., chief of Rx creation at EQRx.

EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

Retrieved on: 
Tuesday, October 19, 2021

Launched in January 2021, the Innovation Passport aims to accelerate treatment through regulatory approval and reimbursement as part of the ILAP.

Key Points: 
  • Launched in January 2021, the Innovation Passport aims to accelerate treatment through regulatory approval and reimbursement as part of the ILAP.
  • The process is also supported by additional bodies including the NHS England, the NHS Improvement, Health Research Authority and the National Institute for Health Research.
  • EQRx holds the development and commercialization rights to aumolertinib outside of Greater China and is pursuing regulatory discussions in multiple countries.
  • In August 2021, EQRx announced a proposed combination with CM Life Sciences III (Nasdaq: CMLTU) to accelerate its growth.

EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs

Retrieved on: 
Wednesday, October 6, 2021

EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.

Key Points: 
  • EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
  • We are excited to work with Absci towards our goal of providing innovative, cost-effective treatment options for patients.
  • This collaboration with EQRx expands the reach of our AI-powered target discovery, drug design and development technology, said Sean McClain, founder and CEO of Absci.
  • EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices.

EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021

Retrieved on: 
Friday, September 17, 2021

GEMSTONE-301 is the first positive Phase 3 trial of a PD-(L)1 agent in this broad Stage III NSCLC patient population setting.

Key Points: 
  • GEMSTONE-301 is the first positive Phase 3 trial of a PD-(L)1 agent in this broad Stage III NSCLC patient population setting.
  • Overall survival (OS) data were immature, but an encouraging trend for a survival benefit with sugemalimab vs. placebo was observed with follow-up of patients ongoing.
  • These data suggest sugemalimab may have the potential to treat a broad population of patients with Stage III NSCLC.
  • The upcoming presentation at ESMO 2021 in Stage III NSCLC builds upon the recent presentation of updated data from the GEMSTONE-302 study in Stage IV NSCLC at the IASLC 2021 World Conference on Lung Cancer, positioning sugemalimab as a potential treatment option to address both Stage III and IV NSCLC.

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC

Retrieved on: 
Tuesday, September 14, 2021

GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).

Key Points: 
  • GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).
  • We look forward to more mature OS data from GEMSTONE-302 as well as continued regulatory discussions for sugemalimab in multiple countries.
  • Details of the presentation are as follows:
    Session: MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
  • Subgroup analysis showed clinical benefit regardless of PD-L1 expression level or pathologic subtype in patients with Stage IV NSCLC.

EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III

Retrieved on: 
Friday, August 6, 2021

Neither EQRx nor CM Life Sciences III gives any assurance that either EQRx or CM Life Sciences III or the combined company will achieve its expectations.

Key Points: 
  • Neither EQRx nor CM Life Sciences III gives any assurance that either EQRx or CM Life Sciences III or the combined company will achieve its expectations.
  • CM Life Sciences III and EQRx also will file other documents regarding the proposed transaction with the SEC.
  • The documents filed by CM Life Sciences III with the SEC also may be obtained free of charge at CM Life Sciences IIIs website at https://iii.cmlifesciencesspac.com/ or upon written request to CM Life Sciences III, c/o Corvex Management, 667 Madison Ave, New York, NY 10065.
  • Information about CM Life Sciences IIIs directors and executive officers and their ownership of CM Life Sciences IIIs securities is set forth in CM Life Sciences IIIs filings with the SEC.

EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines

Retrieved on: 
Wednesday, August 4, 2021

The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.

Key Points: 
  • The collaboration will leverage AbCelleras AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets.
  • The partnership, which spans several therapeutic areas, will help to rapidly expand EQRxs early-stage pipeline of novel medicines.
  • Were proud to partner with EQRx on their bold mission to reimagine drug development and bring medicines to patients faster and at lower cost, said Carl Hansen, Ph.D., CEO of AbCellera.
  • EQRx is committed to catalyzing a market-based solution to one of societys biggest healthcare challenges by developing important new medicines and offering them at lower prices.

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

Retrieved on: 
Thursday, June 24, 2021

Under the terms of the agreement, the strengths of both companies will be leveraged throughout the drug development process.

Key Points: 
  • Under the terms of the agreement, the strengths of both companies will be leveraged throughout the drug development process.
  • Exscientia will lead the discovery phase through to Investigational New Drug application (IND) filing, while EQRx will be responsible for clinical development, regulatory and commercialization efforts.
  • EQRx and Exscientia will equally share in the discovery, development and commercialization costs.
  • Exscientia is a leader in AI-driven drug discovery, and of particular note, has now brought multiple AI-engineered drug candidates to clinical trials.

Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib

Retrieved on: 
Thursday, July 23, 2020

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma; 3692.HK), a leading biopharmaceutical company in China, today announced a strategic collaboration and licensing agreement for almonertinib with EQRx, a biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society.

Key Points: 
  • Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma; 3692.HK), a leading biopharmaceutical company in China, today announced a strategic collaboration and licensing agreement for almonertinib with EQRx, a biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society.
  • Under the terms of the agreement, EQRx will be responsible for the development and commercialization of almonertinib in the United States, Europe, Japan and all other global markets outside of Greater China, and Hansoh Pharma will continue its development and commercialization of almonertinib in Greater China.
  • EQRx and Hansoh will seek to jointly conduct global studies to further expand the potential of almonertinib as a monotherapy and in combination therapy settings.
  • View the full release here: https://www.businesswire.com/news/home/20200723005283/en/
    With a world-class clinical and regulatory team, EQRx is an outstanding partner for Hansoh Pharma to advance the development of almonertinib outside of Greater China, said Aifeng Lyu, Ph.D., President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma.